Today: October 22, 2016, 9:07 am

Global cobicistat market: Latest market analysis presented
Cobicistat (HIV) - Forecast and Market Analysis to 2022 - a new market research report on 2014-03-13 15:40:02
Cobicistat (HIV) - Forecast and Market Analysis to 2022 - GlobalData has released its new PharmaPoint Drug Evaluation report, "Cobicistat (HIV) - Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Gilead has developed a novel pharmacokinetic booster, cobicistat (previously known as GS-9350), which acts as an inhibitor of human cytochrome P450 3A (CYP3A) isoforms. The drug increases the systemic exposure of co-administered medications that are metabolized by CYP3A enzymes, such as protease inhibitors. This increases the co-administered drugs bioavailability, thereby enabling less frequent dosing of the co-administered medications (PIs or elvitegravir). Cobicistats mechanism is similar to AbbVies Norvir (ritonavir), but cobicistat lacks intrinsic antiretroviral activity. When dosed as a booster, the antiretroviral activity of Norvir is minimal, which positions cobicistat as a threat to Norvir as a PK booster, since neither can claim antiviral activity. Studies that compared cobicistat with Norvir used a CYP3A substrate, midazolam for clearance. Both Norvir and cobicistat potently inhibit midazolam from being cleared. That means that a drug that would be metabolized by CYP3A can have sustained antiviral activity in the presence of cobicistat (Mathias et al., 2010). Cobicistat is already approved for use in the US as a component of Gileads Stribild (Sax et al., 2012). Gilead also filed for EMA approval in the EU, and Japan Tobacco filed an application with the Pharmaceuticals and Medical Devices (PMDA) in Japan for a drug with Stribilds formulation in November of 2012. In June 2012, Gilead Sciences also filed a New Drug Application (NDA) with the FDA for approval as a standalone booster to be used with pre-existing PIs that are currently used with AbbVies Norvir (Gilead Sciences, press release, July 24, 2012). GlobalData estimates that cobicistat will be launched in the US and EU in 2013, and in Japan by 2014.


- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cobicistat including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cobicistat for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Cobicistat performance
- Obtain sales forecast for Cobicistat from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 779 Words
Related Articles
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.